Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer

PurposeImmunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AEs)...

Full description

Bibliographic Details
Main Authors: Yahan Huang, Jiao Wang, Yanting Hu, Pikun Cao, Gang Wang, Hongchao Cai, Meixiang Wang, Xia Yang, Zhigang Wei, Xin Ye
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
microwave ablation
camrelizumab
lung cancer
progression-free survival
overall survival
objective response rate
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.938827/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.938827/full

Similar Items